Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 7/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029987 | 0.74 | ACVRL1 (0.52) | ACVRL1EPHB4RAB9ANPC1 | |
| SCHEMBL4259789 | 0.70 | HTR3E (0.35) | ACVRL1EPHB4RAB9ANPC1HTT | |
| SCHEMBL4259923 | 0.68 | SRC (0.56) | EPHB4 | |
| Hydrochloric Acid SCHEMBL4256634 | 0.67 | SRC (0.55) | EPHB4 | |
| Hydrochloric Acid SCHEMBL27711731 | 0.66 | EPHB4 (0.52) | EPHB4 | |
| SCHEMBL5723655 | 0.65 | RAB9A (0.43) | ACVRL1RAB9ANPC1HTTSMN1; SMN2 | |
| SCHEMBL27711772 | 0.64 | SRC (0.39) | ACVRL1RAB9ANPC1HTTSMN1; SMN2 | |
| SCHEMBL3275997 | 0.64 | ACVRL1 (0.48) | ACVRL1EPHB4RAB9ANPC1KDM4E | |
| SCHEMBL17204223 | 0.63 | RAB9A (0.33) | ACVRL1EPHB4RAB9ANPC1HTT | |
| SCHEMBL16042631 | 0.62 | RAB9A (0.36) | RAB9ANPC1HTTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871769-B1 | CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE. | ASTRAZENECA AB (SE) | 2017-02-22 | — | — | EP | disclosed |
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | ACVRL1 4156/4885EPHB4 4067/4885RAB9A 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.